Dr Vu T Nguyen, MD | |
401 S 7th St Ste 4, Akron, PA 17501-1490 | |
(717) 859-1800 | |
(717) 859-1808 |
Full Name | Dr Vu T Nguyen |
---|---|
Gender | Male |
Speciality | Family Practice |
Experience | 24 Years |
Location | 401 S 7th St Ste 4, Akron, Pennsylvania |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1275530669 | NPI | - | NPPES |
100901260006 | Medicaid | PA |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Q00000X | Family Medicine | MD421028 (Pennsylvania) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Lancaster General Hospital | Lancaster, PA | Hospital |
Wellspan Ephrata Community Hospital | Ephrata, PA | Hospital |
Mailing Address | Practice Location Address |
---|---|
Dr Vu T Nguyen, MD 401 S 7th St Ste 4, Akron, PA 17501-1490 Ph: (717) 859-1800 | Dr Vu T Nguyen, MD 401 S 7th St Ste 4, Akron, PA 17501-1490 Ph: (717) 859-1800 |
News Archive
Recommendations of the Neuromodulation Appropriateness Consensus Committee (NACC), announced at the 11th World Congress of the International Neuromodulation Society (INS), address established therapies and preview emerging and potential future advances.
Dining out more at restaurants, cafeterias and fast-food outlets may boost total levels of potentially health-harming chemicals called phthalates in the body, according to a study out today. Phthalates, a group of chemicals used in food packaging and processing materials, are known to disrupt hormones in humans and are linked to a long list of health problems.
From the deepest seafloor to the highest mountain, from the hottest region to the cold Antarctic plateau, environments labelled as extreme are numerous on Earth and they present a wide variety of features and characteristics.
Immunocore Limited, the Oxford-based biotechnology company developing novel biological drugs to treat cancer and viral disease, today announced that it has entered into an oncology research collaboration and licensing agreement with MedImmune, the global biologics research and development arm of AstraZeneca. Both companies will research and develop novel cancer therapies using Immunocore's Immune Mobilising Monoclonal T-Cell Receptor Against Cancer technology.
A Cochrane review of the accuracy of skin cancer diagnostics has found that visual inspection of suspicious lesions is insufficient to ensure an accurate diagnosis.
› Verified 4 days ago